You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial
|
|---|---|
| Published in |
Arthritis Care & Research, May 2016
|
| DOI | 10.1002/acr.22759 |
| Pubmed ID | |
| Authors |
Paul Emery, Roy M. Fleischmann, Ingrid Strusberg, Patrick Durez, Peter Nash, Eric Jason B. Amante, Melvin Churchill, Won Park, Bernardo Pons‐Estel, Chenglong Han, Timothy A. Gathany, Stephen Xu, Yiying Zhou, Jocelyn H. Leu, Elizabeth C. Hsia |
| Abstract |
Evaluate the safety and efficacy of golimumab through 5 years in adults with active RA who had not previously received methotrexate (MTX). In GO-BEFORE, 637 MTX-naïve adult patients with active RA were randomized (1:1:1:1) to placebo+MTX (Group 1), golimumab 100mg+placebo (Group 2), golimumab 50mg+MTX (Group 3), or golimumab 100mg+MTX (Group 4). Inadequate responders in Groups 1, 2, and 3 entered early escape at week28 to golimumab 50mg+MTX, golimumab 100mg+MTX, or golimumab 100mg +MTX, respectively; remaining patients in Group 1 could crossover to golimumab 50mg+MTX at week52. Assessments included ACR20/50/70 response, DAS28-CRP scores, and vdH-mTSS. Efficacy was analyzed using an intent-to-treat analysis. Pharmacokinetics and immunogenicity were evaluated at selected visits. A total of 422 patients completed golimumab treatment through week256. At week256, 72.8%, 54.6%, and 38.0% of all patients in the full ITT population (n=637) had an ACR20/50/70 response, respectively, 84.1% had a good or moderate DAS28-CRP response, and 72.7% had a clinically meaningful improvement in physical function. Radiographic progression was minimal in all treatment groups through week256, and the overall mean change from baseline in vdH-mTSS was 1.36. Serum trough golimumab concentrations were approximately dose proportional and maintained through week256. Antibodies to golimumab occurred in 9.6% of patients through week256. Infections were the most common type of AE; 204/616 patients (33.1%) had ≥1 serious AE. Clinical efficacy with golimumab treatment was maintained through week256 of the GO-BEFORE trial of MTX-naïve RA patients. No unexpected AEs occurred; safety results through 5 years are consistent with earlier reports. This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 122 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 14% |
| Researcher | 12 | 10% |
| Student > Ph. D. Student | 12 | 10% |
| Student > Bachelor | 12 | 10% |
| Professor | 7 | 6% |
| Other | 21 | 17% |
| Unknown | 41 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 34% |
| Nursing and Health Professions | 9 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Immunology and Microbiology | 3 | 2% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 13 | 11% |
| Unknown | 48 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2015.
All research outputs
#18,429,829
of 22,831,537 outputs
Outputs from Arthritis Care & Research
#2,404
of 2,717 outputs
Outputs of similar age
#252,700
of 336,861 outputs
Outputs of similar age from Arthritis Care & Research
#50
of 54 outputs
Altmetric has tracked 22,831,537 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,717 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,861 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.